MedTrace Logo

Breast Cancer After Ovarian Cancer During and/or After Therapy: Genomic Evaluation

NCT05763472 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2023-03-10

No results posted yet for this study

Summary

This study will investigate, in patients with germline BRCA-1/2 mutations and breast cancer, arising during and / or after treatment with platinum-based chemotherapy and / or with PARP-inhibitors for ovarian cancer, the presence of molecular alterations potentially involved in the mechanisms of resistance to antineoplastic treatment on breast and ovarian tumor tissue.

Conditions

  • BRCA-Associated Breast Carcinoma

Interventions

GENETIC

Next-generation sequencing (NGS) assay TruSight Oncology 500 (TSO 500).

Next-generation sequencing (NGS) analysis with TruSight Oncology 500 (TSO 500) is performed on tumor samples from breast and ovarian cancer of the enrolled patients.

Sponsors & Collaborators

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS

    lead OTHER

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-01
Primary Completion
2023-06-01
Completion
2023-06-01

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05763472 on ClinicalTrials.gov